Epizyme Inc. [EPZM] fell -50.41% so far this year. What now?

Epizyme Inc. [NASDAQ: EPZM] plunged by -$0.89 during the normal trading session on Monday and reaching a high of $13.31 during the day while it closed the day at $12.20. The company report on November 12, 2020 that Epizyme to Participate in Jefferies Virtual London Healthcare Conference.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that Robert Bazemore, president and chief executive officer, will participate in a fireside chat during the Jefferies Virtual London Healthcare Conference on Thursday, Nov. 18, 2020 at 12:35 p.m. ET.

A live webcast of the fireside chat will be available in the investor section of the company’s website and will be archived for 60 days following the presentation.

Epizyme Inc. stock has also loss -11.21% of its value over the past 7 days. However, EPZM stock has declined by -3.71% in the 3 months of the year. Over the past six months meanwhile, it has lost -31.46% and lost -50.41% year-on date.

The market cap for EPZM stock reached $1.23 billion, with 101.51 million shares outstanding and 82.92 million shares in the current float. Compared to the average trading volume of 936.40K shares, EPZM reached a trading volume of 1403784 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Epizyme Inc. [EPZM]:

Oppenheimer have made an estimate for Epizyme Inc. shares, keeping their opinion on the stock as Perform, with their previous recommendation back on April 01, 2020. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on March 04, 2020, representing the official price target for Epizyme Inc. stock. Previously, the target price had yet another raise from $25 to $36, while H.C. Wainwright kept a Buy rating on EPZM stock.

The Average True Range (ATR) for Epizyme Inc. is set at 0.85, with the Price to Sales ratio for EPZM stock in the period of the last 12 months amounting to 105.20. The Price to Book ratio for the last quarter was 5.95, with the Price to Cash per share for the same quarter was set at 2.77.

EPZM stock trade performance evaluation

Epizyme Inc. [EPZM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.21. With this latest performance, EPZM shares dropped by -9.96% in over the last four-week period, additionally sinking by -31.46% over the last 6 months – not to mention a drop of -33.04% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EPZM stock in for the last two-week period is set at 48.73, with the RSI for the last a single of trading hit 46.50, and the three-weeks RSI is set at 48.70 for Epizyme Inc. [EPZM]. The present Moving Average for the last 50 days of trading for this stock 12.39, while it was recorded at 13.00 for the last single week of trading, and 15.10 for the last 200 days.

Epizyme Inc. [EPZM]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Epizyme Inc. [EPZM] shares currently have an operating margin of -744.29. Epizyme Inc.’s Net Margin is presently recorded at -715.53.

Return on Total Capital for EPZM is now -56.92, given the latest momentum, and Return on Invested Capital for the company is -54.99. Return on Equity for this stock declined to -60.37, with Return on Assets sitting at -48.25. When it comes to the capital structure of this company, Epizyme Inc. [EPZM] has a Total Debt to Total Equity ratio set at 17.59. Additionally, EPZM Total Debt to Total Capital is recorded at 14.96, with Total Debt to Total Assets ending up at 13.54. Long-Term Debt to Equity for the company is recorded at 18.80, with the Long-Term Debt to Total Capital now at 14.18.

Reflecting on the efficiency of the workforce at the company, Epizyme Inc. [EPZM] managed to generate an average of -$838,892 per employee. Receivables Turnover for the company is 1.96 with a Total Asset Turnover recorded at a value of 0.07.Epizyme Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.70 and a Current Ratio set at 8.90.

Earnings per share (EPS) analysis for Epizyme Inc. [EPZM] stock

With the latest financial reports released by the company, Epizyme Inc. posted -0.59/share EPS, while the average EPS was predicted by analysts to be reported at -0.5/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -18.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EPZM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Epizyme Inc. go to 38.00%.

Epizyme Inc. [EPZM]: Insider Ownership positions

There are presently around $1,125 million, or 95.30% of EPZM stock, in the hands of institutional investors. The top three institutional holders of EPZM stocks are: PRIMECAP MANAGEMENT CO/CA/ with ownership of 15,068,427, which is approximately 0.084% of the company’s market cap and around 0.60% of the total institutional ownership; RP MANAGEMENT, LLC, holding 9,166,667 shares of the stock with an approximate value of $111.83 million in EPZM stocks shares; and REDMILE GROUP, LLC, currently with $101.4 million in EPZM stock with ownership of nearly -2.05% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in Epizyme Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 78 institutional holders increased their position in Epizyme Inc. [NASDAQ:EPZM] by around 7,955,044 shares. Additionally, 74 investors decreased positions by around 8,831,965 shares, while 32 investors held positions by with 75,394,662 shares. The mentioned changes placed institutional holdings at 92,181,671 shares, according to the latest SEC report filing. EPZM stock had 30 new institutional investments in for a total of 2,130,945 shares, while 32 institutional investors sold positions of 5,745,597 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam